HER2/ERBB2 is a transmembrane protein that induces tumour initiation and progression; therefore, HER2 potentially represents an ideal target, and the safety of CAR-T-HER2 has been confirmed in a phase I trial (NCT01935843) [178]. The gene discussed is ERBB2; the disease is neoplasm.